Transgene Financial Statements From 2010 to 2024
| TRGNF Stock | USD 1.59 0.00 0.00% |
Check Transgene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transgene's main balance sheet or income statement drivers, such as , as well as many indicators such as . Transgene financial statements analysis is a perfect complement when working with Transgene Valuation or Volatility modules.
Transgene |
Transgene SA Company Return On Equity Analysis
Transgene's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Transgene Return On Equity | -0.36 |
Most of Transgene's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transgene SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Transgene SA has a Return On Equity of -0.3623. This is 98.49% lower than that of the Healthcare sector and 99.01% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 16.87% higher than that of the company.
Transgene SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Transgene's current stock value. Our valuation model uses many indicators to compare Transgene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Transgene competition to find correlations between indicators driving Transgene's intrinsic value. More Info.Transgene SA is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Transgene's earnings, one of the primary drivers of an investment's value.About Transgene Financial Statements
Transgene stakeholders use historical fundamental indicators, such as Transgene's revenue or net income, to determine how well the company is positioned to perform in the future. Although Transgene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Transgene's assets and liabilities are reflected in the revenues and expenses on Transgene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Transgene SA. Please read more on our technical analysis and fundamental analysis pages.
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.